Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-003 in Chronic Rhinosinusitis With Nasal Polyps
NCT07313917Phase 2Not yet recruiting
- Sponsor
- LongBio Pharma
- Start
- Jan 2026
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LP-003 in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by LongBio Pharma. Primary endpoints: Change from baseline in Nasal Polyps Score at Week 24 and Change from baseline in Nasal Congestion Score at Week 24. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
LP-003
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT07313917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07313917.